Thomas Myers MD’s Post
1mo
TB-500 is a peptide I get asked about almost weekly, and the honest answer is the same one I give for most compounds in this space. The animal data on Thymosin Beta-4 is genuinely interesting. Studies in tendon, muscle, and cardiac tissue have shown accelerated healing, improved cell migration to injury sites, and modulation of the inflammatory response that drives chronic tendinopathy. The mechanism is plausible. The pre-clinical signal has been consistent enough that the field has been paying attention for over a decade. The human trial data is sparse. There are case series. There is observational data from sports medicine settings where the compound has been used off-label for years. There is no large randomized controlled trial that would let me recommend it in the way I would recommend a structural treatment with established evidence. What I can tell you is what I observe. Across patients who arrive at the operating room having used TB-500 as part of a structured pre-operative protocol for a rotator cuff or chronic tendon problem, the tissue handling is often different. The tendon has more substance under the suture. Retraction is sometimes less than the imaging predicted. The capsule and surrounding soft tissue look better perfused. I cannot prove from any single case that the peptide is responsible. The patients on these protocols are usually doing other things right too. Better sleep. Better nutrition. Structured loading work. The peptide is one variable in a stack. That is the honest framing. Layered onto a thoughtful foundation, the observational signal is real. As an isolated intervention in patients doing nothing else, the evidence is much weaker. I do not prescribe TB-500 cavalierly. When I do recommend it, the indication is specific, the dosing is structured, and the patient has already addressed the foundation that makes the peptide work do what it is supposed to do. If a clinic is offering it as a standalone intervention without that foundation, you are not getting the benefit the literature is gesturing at. What is the rest of the protocol around the peptide? See more comments
Explore content categories